Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Symptoms and General Pathology

Digestive System Diseases

Breast Neoplasms

Prostatic Neoplasms

Neoplastic Cells, Circulating

Colorectal Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Neoplasm Metastasis

Neoplastic Processes

Confirmed patients with breast, prostate, or colorectal cancer (OR) subjects with no prior history of cancer

Pedro M Sanz-Altamira, MD, PhD

Objective: To test the sensitivity of a proprietary novel filtration device designed to capture and concentrate circulating tumor cells (CTCs).

Collection of Blood Specimens for Circulating Tumor Cell Analysis

Blood samples will be collected from study subjects and analyzed for the number of circulating tumor cells (CTCs) within 96 hours of blood collection.

Commonwealth Hematology-Oncology, P.C.

Viatar LLC

Antineoplastic Agents

All Drugs and Chemicals

Herbal and Botanical

Fulvestrant

Immunomodulating Agents

Palbociclib

Chrysanthemum

Monitoring of patients with tumours treated by immune therapy.

Timing of blood sampling:

* inclusion
* after #8 weeks on therapy
* at progression or 6 months from inclusion for patient without progressive disease
* if toxicity grade 3 or 4, or grade 2 until 1 month.

Monitoring of patients with HER 2+/- breast cancer and correlation with genome-wide copy number, loss of heterozygosity detection, as well as identification of frequently tested somatic mutations (Oncoscan® assays).

Timing of blood sampling:

* inclusion
* after 1 cycle of therapy (weeks 3-4)
* up to 2 other samples, timepoints decided by the investigator

Feasibility of Proximity-Ligation Assay (PLA) to study membrane proteins dimerisation by on isolated tumour cells in patients with HER2+/- breast cancer (HER 2+/-).

One tumor sampling.

Timing of blood sampling:

* Inclusion
* up to 3 other samples, timepoints decided by the investigator.

Establishment of xenografts from tumor (PDX) and from Circulating Tumour Cell (CDX) by tumour and blood sampling.

One tumor sampling.

Timing of blood sampling:

* Inclusion
* up to 3 other samples, timepoints decided by the investigator.

Follow-up of patients previously treated by neoadjuvant chemotherapy for triple negative breast cancer.

Timing of blood sampling:

* Inclusion
* up to 3 other samples, timepoints decided by the investigator.

Monitoring of patients treated with palbociclib

Timing of blood sampling:

* Inclusion day (2 samples)
* after #2 weeks of therapy
* after #4 weeks of therapy
* at progression.

Detection of PD-L1 in metastatic breast cancer patients

Timing of blood sampling:

* Inclusion
* up to 3 other samples, timepoints decided by the investigator.

Detection of PD-L1 in metastatic lung cancer patients

Timing of blood sampling:

* Inclusion
* up to 3 other samples, timepoints decided by the investigator.

Monitoring of patients with Non-Small Cell lung Cancer treated by immune therapy.

Blood sampling at 4 timepoints.

Monitoring of patient with a metastatic breast cancer treated by palbociclib.

Timing of blood sampling:

* Inclusion
* after #4 weeks of therapy
* at the first tumoral evaluation (month 3 or 4)
* at progression.

The cohort includes all patients with bone or soft tissue sarcoma. Timing of blood sampling depending on disease staging.

Monitoring of patient with a metastatic breast cancer initiating a treatment by Faslodex-Afinitor.

Timing of blood sampling:

* Inclusion
* after #3-5 weeks of therapy
* at the first tumoral evaluation (month 2 or 3)
* at progression.

The cohort concerns patients with uveal melanoma in the 1st systemic line at the metastatic stage (may have had prior adjuvant therapy or surgery/radiofrequency).

Timing of blood sampling:

* J1C1
* J2C1
* J1C2
* J1C5 (first tumoral evaluation).

This cohort concerns patients with metastatic Non-Small Cell lung Cancer receiving anti-PD-1/PD-L1.

One tumour sampling.

Timing of blood sampling:

* before treatment
* at W8 of treatment (after radiological examination)
* at W12 of treatment
* at progression or 18 months after the beginning of treatment

This cohort concerns patients with metastatic lobular breast cancer One tumour sampling.

Timing of blood sampling:

* At inclusion
* After biopsy post inclusion (or in 15 days after)
* after 1 or 2 months of treatment
* at progression or 18 months after inclusion

This cohort concerns patients with metastatic uveal melanoma before immunotherapy treatment.

Timing of blood sampling :

* at inclusion
* at cycle 2 or 3 of treatment
* at the first tumoral evaluation (C5D1)
* at progression

Up to 5 blood samplings can be performed at different time points

Blood sampling

One tumor sampling can be performed, if applicable

Tumor sampling

Stool sampling

François-Clément BIDARD, MD PhD

Exploratory study on blood-borne biological markers and their correlation with clinical and pathological characteristics.

Exploratory multi-cohort study including different types of cancer (different organs and/or different histological types).

Each kind of blood-borne biological markers analyses corresponds to a cohort.

Analysis of Circulating Tumor Markers in the Blood (ALCINA)

Analysis of Circulating Tumor Markers in the Blood

Sponsor will share de-identified data sets. Documents generated under the project will be disseminated in accordance with Institut Curie policies.

Success rate of the tested detection techniques. The success rate of a given detection technique is calculated by the ratio " detection success " / " number of screened patients ".

Number of biological analysis results correlated to clinical data. Establishment of a proof of concept

Institut Curie

Gland and Hormone Related Diseases

Rare Diseases

Pancreatic Neoplasms

Adenocarcinoma

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Pancreatic Cancer

Gastrointestinal Agents

Pancrelipase

Pancreatin

Patients with recent diagnosis of pancreatic ductal adenocarcinoma (PDAC) or with strong suspicion PDAC

Blood samples

Portal vein blood sample during surgery procedure for the Pancreatic Ductal Adenocarcinoma group

Portal vein blood sample

Etienne BUSCAIL

The proposal aims at determining whether liquid biopsy approaches are valid in the diagnosis of pancreatic cancer. Step1 will test 3 CTC isolation methods and analyse by flow cytometry the presence of onco-exosomes in the culture media of pancreatic cell lines. Step 2 will examine the diagnostic accuracy of these blood tumor elements for the diagnosis of cancer of patients with PDAC suspicion or recent diagnosis and their value for disease monitoring.

Pancreatic ductal adenocarcinoma (PDAC) incidence has increased with a high rate during the past few years (+4.7% per year between 2005 and 2012, source InfoCancer 2013). No cure is currently available for this deadly disease, with an overall survival \<5%. Survival can reach 20% when surgery is possible, giving the best chance to the patients. If patients present locally advance disease, it is crucial to quickly establish resectability to avoid unneeded and even deleterious surgery in patients with metastatic stages. It is also important to increase the rate of true R0 resection with effective preoperative therapy. However, when the cancer is suspected, neoadjuvant chemotherapies are often delayed because the mandatory histologic proof is difficult to make with non-informative biopsies. It is necessary to find new markers to help for rapid diagnosis that could allow neoadjuvant therapies and surgery when anatomo-pathologic proof is not available. New developments in the field of liquid biopsy hold great promise in providing valuable information for diagnosis assistance. The project will be run in two steps. First, several methods will be compared for tumor cell recovery after cell spiking in blood of non-cancer patients and pancreatic cell line onco-exosomes will characterized by flow cytometry. Second the best method will be used to detect and enumerate CTCs in 20 PDAC patients and 20 non-cancer patients. In parallel GPC1+ exosomes from patients' plasmas will be quantified. Diagnosis accuracy will be established and compared. Correlations between circulating tumor elements presence and clinical and biological parameters will be evaluated at the time of the diagnosis. Patient clinical outcome will be assessed according to initial circulating element quantification.

Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC

Estimation with bilateral confidence interval of 95%. A mixed affect linear regression will be operated to obtain this estimation.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Collection of Blood Specimens for Circulating Tumor Cell Analysis	NCT01943500	Breast Cancer Prostate Cancer Colorectal Canc...		18 Years -	Viatar LLC
Analysis of Circulating Tumor Markers in the Blood (ALCINA)	NCT02866149	Cancer	Blood sampling Tumor sampling Stool sampling	18 Years -	Institut Curie
Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC	NCT03032913	Pancreatic Duct...	Blood samples Portal vein blo...	18 Years -	University Hospital, Bordeaux
Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC	NCT03032913	Pancreatic Duct...	Blood samples Portal vein blo...	18 Years -	University Hospital, Bordeaux
Analysis of Circulating Tumor Markers in the Blood (ALCINA)	NCT02866149	Cancer	Blood sampling Tumor sampling Stool sampling	18 Years -	Institut Curie

Spots Global Cancer Trial Database for circulating tumor cell (ctc)